OptimizeRx Corp’s amended ownership disclosure lists Royce & Associates as beneficial owner of 1,315,057 common shares, equal to 6.98% of the class as of September 30, 2026. The ownership table reports sole voting and dispositive power over 1,315,057 shares, with no shared voting or dispositive power. An exhibit says the securities are held by investment-company or other managed-account clients of Royce & Associates, LP, which disclaims pecuniary interest and beneficial ownership.
OptimizeRx Corp (OPRX) Chief Business Officer Andrew J. D'Silva had 414 shares withheld by the issuer on October 1, 2026, upon vesting of restricted stock units to satisfy tax withholding obligations. The reported price was $8.39 per share; his resulting direct holdings were 99,246 shares.
OptimizeRx Corp (OPRX) reported that Chief Business Officer Andrew J. D'Silva had 1,432 shares of common stock withheld on September 1, 2026 to satisfy tax withholding obligations upon vesting of restricted stock units, treated as a disposition under Section 16, at a value of $7.86 per share. After this withholding, he directly holds 99,660 shares of OptimizeRx common stock, and no Rule 10b5-1 trading plan is reported.
OptimizeRx Corp (symbol: OPRX) is the issuer of record for a Form 4 filing submitted to the SEC.
OptimizeRx Corp (symbol: OPRX) is the issuer of record for a Form 4 filing submitted to the SEC.
OptimizeRx Corp (symbol: OPRX) is the issuer of record for a Form 4 filing submitted to the SEC.
OptimizeRx Corp (symbol: OPRX) is the issuer of record for a Form 4 filing submitted to the SEC.
OptimizeRx Corp (OPRX) reported an insider transaction by Chief Operating Officer Brendan W. Merrell. On 2026-08-21, 1,020 shares of common stock were withheld at $7.71 per share to satisfy tax withholding obligations upon the vesting of restricted stock units. This withholding is treated as a disposition under Section 16, and Merrell now holds 25,187 shares of common stock directly.
OptimizeRx Corp (OPRX) reported that Chief Executive Officer Stephen L. Silvestro had 1,737 shares of Common Stock withheld on 2026-08-21 to satisfy his tax withholding obligations upon the vesting of restricted stock units. This Code F transaction is treated as a disposition under Section 16, and Silvestro now holds 183,551 shares of OptimizeRx common stock directly.
OptimizeRx Corp (OPRX) reported that Chief Legal & Admin Officer Marion Odence-Ford had 1,529 shares of common stock withheld on 2026-08-21 to satisfy tax withholding obligations upon vesting of restricted stock units. This withholding is treated as a disposition under Section 16. After this transaction, Odence-Ford directly held 90,407 shares of OptimizeRx common stock.